Winrevair®

Přípravek Winrevair® je indikován k léčbě plicní arteriální hypertenze (PAH) v kombinaci s jinými terapiemi PAH u dospělých pacientů s funkční třídou dle WHO (WHO FC) II až III ke zlepšení zátěžové kapacity.

1. Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478-1490. 2. Merck receives priority review from FDA for new biologies license application for sotatercept, an activin signaling inhibitor to treat adults with pulmonary arterial hypertension (PAH). News release. Merck. September 28, 2023. Accessed February 16, 2024. https://www.merck.com/news/merck-receives-priority-review-from-fda-for-new-biologics-license-application-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension-pah/ 3. Treposuvi. Summary of Product Characteristics. AOP Orphan Ltd; 2023. 4. Adempas. Summary of Product Characteristics. Bayer AG; 2023. 5. Ventavis. Summary of Product Characteristics. Bayer AG; 2023. 6. Adcirca. Summary of Product Characteristics. Eli Lilly Nederland BV; 2023. 7. Volibris. Summary of Product Characteristics. GlaxoSmithKline (Ireland) Limited; 2021. 8. Opsumit. Summary of Product Characteristics. Janssen-Cilag International NV; 2023. 9. Tracleer. Summary of Product Characteristics. Janssen-Cilag International NV; 2023.10. Uptravi. Summary of Product Characteristics. Janssen-Cilag International NV; 2022. 11. Flolan. Summary of product characteristics, labelling and package leaflet. EMA; 2012. 12. Revatio. Summary of Product Characteristics. Upjohn EESV; 2023.